Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Switzerland / NCT07554105
Recruiting Not applicable

Effect of Transcranial Random Noise Stimulation on the Performance in Language Tasks

NCT07554105 · tracked via the Priya Life Science Switzerland tracker
Sponsor
Adrian Guggisberg
Phase
Not applicable
Started
2026-03-17
Last updated
2026-04-28

Condition(s) studied

Healthy Adult Participants

Investigational drug(s) / intervention(s)

transcranial random noise stimulationsham stimulation

transcranial random noise stimulation: active HD-tRNS

sham stimulation: current will be ramped up for 30 seconds and then switched of, to mimic the subjective sensation of tRNS.

Study summary

Language is an essential part of daily life, enabling us to communicate, understand others, read, and learn. Certain brain injuries can disrupt these abilities, and current treatments do not always lead to a full recovery. To improve future therapeutic approaches, it is necessary to better understand how the brain processes language and how its activity can be modulated.

This study aims to evaluate the effects of a non-invasive brain stimulation technique called transcranial random noise stimulation. This method involves applying a very weak electrical current to the scalp to modulate the activity of brain regions involved in language. It is commonly used in research and is considered safe when administered in accordance with current guidelines.

Healthy adult volunteers will participate in this study. Each participant will take part in two sessions spaced about a week apart. During one session, active stimulation will be used, and during the other, placebo stimulation will be used. Placebo stimulation resembles the actual stimulation but has no active effect. Neither the participants nor the researchers will know which type of stimulation is being used during each session.

During the sessions, participants will perform various language tasks, and their brain activity will be recorded using an electroencephalogram (EEG), a painless method.

This study does not provide any direct benefit to participants. The risks are low and limited to temporary sensations, such as a tingling sensation on the scalp. The results will provide a better understanding of how the brain processes language and could eventually contribute to the development of new rehabilitation approaches.

Eligibility

Sex
ALL
Min age
18 Years
Max age
90 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Age: 18-35 years or 60-90 years * Native French speakers * Right handed * Willing and able to provide informed consent * Normal or corrected-to-normal vision and hearing Exclusion Criteria: * History of neurological or psychiatric disease * Regular consumption of benzodiazepines, neuroleptics, or psychoactive drugs * Major language deficit, developmental language disorder, arthropathies and other mechanical language impairments * Inability to understand or follow study procedures * Contraindications to brain stimulation, such as * History of epilepsy or severe migraine * Pacemaker or other active implants * Metallic objects in the head * Skull breach such as craniotomy * Pregnancy

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Division of Neurorehabilitation, University Hospital of Geneva Geneva Canton of Geneva Recruiting

More Adrian Guggisberg trials in Switzerland

Neurofeedback-based Visual Restoration Therapy Recruiting

Other trials for the same condition

The Effect of Olive Leaf Extract Supplementation on Training-induced Skeletal Muscle Functional and Molecular Adaptations in Healthy Volunteers Starting soon
Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With Migraine Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07554105 on ClinicalTrials.gov ↗ ← All trials in Switzerland